OBJECTIVES: To estimate the prevalence of cellac disease (CD) in pediatric and adult type 1 diabetes melitus in a defined population and to describe clinical features and HLA class II genotypes predictive of CD in screened patients with type 1 diabetes. PATIENTS AND METHODS: All residents of Olmsted County, Minnesota, with type 1 diabetes mellitus on the prevalence date January 1, 2001, were identified with the use of an established medical records linkage system (Rochester Epidemiology Project) and defined clinical criteria. Consenting patients underwent serologic screening with endomyslal antibody and tissue transglutaminase antibody testing and Intestinal biopsies to confirm the diagnosis of CD. A subset of screened patients also underwent HLA class II genotyping. Quality-of-life screening (Medical Outcomes Study 36-Item Short-Form Health Survey) was completed in a subset of patients at the time of serologic screening. RESULTS: Overall, 392 Olmsted County residents with type 1 diabetes on January 1, 2001, were Identified. A total of 158 patients with type 1 diabetes were tested, representing 40% (158/392) of the enumerated diabetic population, and 11 had biopsy-proven CD for an estimated point prevalence of 7.0% (95% confidence Interval, 3.5%-12.1%). Most CD-positive diabetic patients were asymptomatic and expressed an at-risk CD haplotype with at least one of but not both HLA DQ2 or DQ8. CONCLUSIONS: Celiac disease Is not rare In North American patients with type 1 diabetes, and most CD-positive diabetic patients are asymptomatic Irrespective of age at screening.
OBJECTIVES: To estimate the prevalence of cellac disease (CD) in pediatric and adult type 1 diabetes melitus in a defined population and to describe clinical features and HLA class II genotypes predictive of CD in screened patients with type 1 diabetes. PATIENTS AND METHODS: All residents of Olmsted County, Minnesota, with type 1 diabetes mellitus on the prevalence date January 1, 2001, were identified with the use of an established medical records linkage system (Rochester Epidemiology Project) and defined clinical criteria. Consenting patients underwent serologic screening with endomyslal antibody and tissue transglutaminase antibody testing and Intestinal biopsies to confirm the diagnosis of CD. A subset of screened patients also underwent HLA class II genotyping. Quality-of-life screening (Medical Outcomes Study 36-Item Short-Form Health Survey) was completed in a subset of patients at the time of serologic screening. RESULTS: Overall, 392 Olmsted County residents with type 1 diabetes on January 1, 2001, were Identified. A total of 158 patients with type 1 diabetes were tested, representing 40% (158/392) of the enumerated diabetic population, and 11 had biopsy-proven CD for an estimated point prevalence of 7.0% (95% confidence Interval, 3.5%-12.1%). Most CD-positive diabeticpatients were asymptomatic and expressed an at-risk CD haplotype with at least one of but not both HLA DQ2 or DQ8. CONCLUSIONS: Celiac disease Is not rare In North American patients with type 1 diabetes, and most CD-positive diabeticpatients are asymptomatic Irrespective of age at screening.
Authors: J Seissler; M Schott; S Boms; U Wohlrab; B Ostendorf; N G Morgenthaler; W A Scherbaum Journal: Diabetologia Date: 1999-12 Impact factor: 10.122
Authors: T Not; A Tommasini; G Tonini; E Buratti; M Pocecco; C Tortul; M Valussi; G Crichiutti; I Berti; C Trevisiol; E Azzoni; E Neri; G Torre; S Martelossi; M Soban; A Lenhardt; L Cattin; A Ventura Journal: Diabetologia Date: 2001-02 Impact factor: 10.122
Authors: D Hansen; F N Bennedbaek; L K Hansen; M Høier-Madsen; L S Hegedü; B B Jacobsen; S Husby Journal: Acta Paediatr Date: 2001-11 Impact factor: 2.299
Authors: Rakesh Amin; Nuala Murphy; Julie Edge; Marion L Ahmed; Carlo L Acerini; David B Dunger Journal: Diabetes Care Date: 2002-07 Impact factor: 19.112
Authors: Amanda K Cartee; Lisa A Owens; Brian D Lahr; Barbara P Yawn; Joseph A Murray; Yogish C Kudva Journal: Mayo Clin Proc Date: 2016-08 Impact factor: 7.616
Authors: Jacalyn A See; Katri Kaukinen; Govind K Makharia; Peter R Gibson; Joseph A Murray Journal: Nat Rev Gastroenterol Hepatol Date: 2015-09-22 Impact factor: 46.802
Authors: Heather J Galipeau; Nestor E Rulli; Jennifer Jury; Xianxi Huang; Romina Araya; Joseph A Murray; Chella S David; Fernando G Chirdo; Kathy D McCoy; Elena F Verdu Journal: J Immunol Date: 2011-09-12 Impact factor: 5.422